Informacje techniczne w skrócie. Leczenie bólu w OA

Piśmiennictwo

Cachon T., Frykman O., Innes J.F. et al.: COAST Development Group’s international consensus guidelines for the treatment of canine osteoarthritis. „Front Vet Sci”, 2023.

Gruen M.E., Lascelles B.D.X., Colleran E. et al.: 2022 AAHA pain management guidelines for dogs and cats. „J Am Anim Hosp Assoc”, 2022, 58, 55-76.

Monteiro B.P., Lascelles B.D., Murrell J. et al.: 2022 WSAVA guidelines for the recognition, assessment and treatment of pain. „J Small Anim Pract”, 2023, 64, 177-254.

Librela (bedinvetmab injection) prescribing information. NADA 141-562. Zoetis Inc., May 2023.

Enomoto M., Mantyh P.W., Murrell J. et al.: Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. „Vet Rec”, 2019, 184, 23.

Isola M., Ferrari V., Miolo A. et al.: Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteoarthritis. „Vet Comp Orthop Traumatol”, 2011, 24, 279-284.

Yamazaki A., Edamura K., Tomo Y. et al.: Variations in gene expression levels with severity of synovitis in dogs with naturally occurring stifle osteoarthritis. „PLoS ONE”, 2021, 16.

Corral M.J., Moyaerta H., Fernandes T. et al.: A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. „Vet Anaesthesia Analgesia”, 2021, 48 (6), 943-955.

Michels G.M., Honsberger N.A., Walters R.R. et al.: A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. „Vet Anaesthesia Analgesia”, 2023, 50 (5), 446-458.

Krautmann M., Walters R., Cole P. et al.: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. „Vet J”, 2021, 276.

ZMR Kynetec PetTr...